Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Author:
Riva Laura, Yuan Shuofeng, Yin XinORCID, Martin-Sancho Laura, Matsunaga Naoko, Pache LarsORCID, Burgstaller-Muehlbacher SebastianORCID, De Jesus Paul D., Teriete Peter, Hull Mitchell V., Chang Max W., Chan Jasper Fuk-Woo, Cao Jianli, Poon Vincent Kwok-Man, Herbert Kristina M., Cheng Kuoyuan, Nguyen Tu-Trinh H., Rubanov Andrey, Pu Yuan, Nguyen Courtney, Choi Angela, Rathnasinghe Raveen, Schotsaert MichaelORCID, Miorin Lisa, Dejosez Marion, Zwaka Thomas P., Sit Ko-Yung, Martinez-Sobrido LuisORCID, Liu Wen-Chun, White Kris M.ORCID, Chapman Mackenzie E., Lendy Emma K., Glynne Richard J., Albrecht RandyORCID, Ruppin Eytan, Mesecar Andrew D.ORCID, Johnson Jeffrey R., Benner Christopher, Sun RenORCID, Schultz Peter G., Su Andrew I.ORCID, García-Sastre AdolfoORCID, Chatterjee Arnab K.ORCID, Yuen Kwok-YungORCID, Chanda Sumit K.ORCID
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Reference68 articles.
1. Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475–481 (2020). 2. Sbrissa, D., Naisan, G., Ikonomov, O. C. & Shisheva, A. Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation. PLoS ONE 13, e0204532 (2018). 3. Billich, A. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs 10, 53–59 (2007). 4. Cai, X. et al. PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling. Chem. Biol. 20, 912–921 (2013). 5. World_Health_Organization. Coronavirus Disease (COVID-19) Pandemic https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (2020).
Cited by
641 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|